This application seeks support for a post-doctoral training program in urology based in the Scott Department of Urology at Baylor College of Medicine. The SDU has major ongoing clinical activities, as well as basic research with an emphasis in Prostate Biology, Male Reproductive Biology and Pediatric Urology/Developmental Biology. There are 20 training faculty, 8 of whom have primary appointments in Urology. The training faculty includes 7 M.D.s, 12 Ph.D.s, and 1 M.D./Ph.D. Dr. Lamb will serve as Principal Investigator of the T3 proposal, Dr. Morton will be PI of the K12 proposal, and Dr. Lipshultz will serve as the Director of the Fellowship Training Program. The major research areas in the program include: prostate biology, cell biology, steroid hormone receptors, male reproductive biology, genetics, cell cycle control, aging, human benign prostatic hyperplasia, pediatric urology/developmental biology, gene therapy, and cloning genes. The trainees will be Ph.D. candidates, most likely joining the program directly from completion of graduate school. A focus of our program will be the attraction of highly qualified trainees who seek and intensive substantial research training in Prostate biology, Male Reproductive Biology and Pediatric urology/Developmental Biology, with an emphasis on the clinical translation of the basic research. We have developed a strong recruitment plan, emphasizing the career development of women and minorities in the field. Strengths of the training environment include highly respected, experienced faculty, a high national ranking for research funding, a structured mentoring program and required coursework, a cell biology graduate student program with relevant course work and overall depth in cell biology. Our long-term goals are to train these young investigators to compete successfully for peer-reviewed funding and eventually to increase basic research efforts in Urology.

National Institute of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Institutional National Research Service Award (T32)
Project #
Application #
Study Section
Special Emphasis Panel (ZDK1-GRB-D (O1))
Program Officer
Bishop, Terry Rogers
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Baylor College of Medicine
Schools of Medicine
United States
Zip Code
Haller, Meade; Au, Jason; O'Neill, Marisol et al. (2018) 16p11.2 transcription factor MAZ is a dosage-sensitive regulator of genitourinary development. Proc Natl Acad Sci U S A 115:E1849-E1858
Haller, Meade; Mo, Qianxing; Imamoto, Akira et al. (2017) Murine model indicates 22q11.2 signaling adaptor CRKL is a dosage-sensitive regulator of genitourinary development. Proc Natl Acad Sci U S A 114:4981-4986
Vital, Paz; Castro, Patricia; Ittmann, Michael (2016) Oxidative stress promotes benign prostatic hyperplasia. Prostate 76:58-67
Gomez, Lissette; Kovac, Jason R; Lamb, Dolores J (2015) CYP17A1 inhibitors in castration-resistant prostate cancer. Steroids 95:80-7
Whirledge, Shannon D; Garcia, Jose M; Smith, Roy G et al. (2015) Ghrelin partially protects against cisplatin-induced male murine gonadal toxicity in a GHSR-1a-dependent manner. Biol Reprod 92:76
Vital, Paz; Castro, Patricia; Tsang, Susan et al. (2014) The senescence-associated secretory phenotype promotes benign prostatic hyperplasia. Am J Pathol 184:721-31
Kovac, J R; Gomez, L; Smith, R P et al. (2014) Measurement of endothelial dysfunction via peripheral arterial tonometry predicts vasculogenic erectile dysfunction. Int J Impot Res 26:218-22
Nakka, Manjula; Agoulnik, Irina U; Weigel, Nancy L (2013) Targeted disruption of the p160 coactivator interface of androgen receptor (AR) selectively inhibits AR activity in both androgen-dependent and castration-resistant AR-expressing prostate cancer cells. Int J Biochem Cell Biol 45:763-72
Smith, Phillip P; Smith, Christopher P; Boone, Timothy B et al. (2007) Is abdominal wall contraction important for normal voiding in the female rat? BMC Urol 7:5
Agoulnik, Irina U; Vaid, Ajula; Nakka, Manjula et al. (2006) Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer. Cancer Res 66:10594-602

Showing the most recent 10 out of 21 publications